Mode
Text Size
Log in / Sign up

Sumatriptan/naproxen sodium and ibuprofen show significant pain freedom for pediatric migraine treatmentNew analysis shows effective migraine treatments for children and adolescents

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider sumatriptan/naproxen sodium or ibuprofen for significant pain freedom in pediatric migraine patients.

This network meta-analysis synthesized data from 30 studies involving 8,914 participants to evaluate the efficacy of various acute migraine medications in children and adolescents. The analysis focused on pain freedom at 2 hours, pain relief at 2 hours, and reduction in rescue drug use.

Key findings indicate that sumatriptan/naproxen sodium (OR: 2.91; 95% CI: 1.87-4.53) and ibuprofen (OR: 2.88; 95% CI: 1.47-5.64) showed significantly higher odds of pain freedom at 2 hours compared to placebo. Additionally, sumatriptan/naproxen sodium was the only treatment associated with a significantly higher OR for pain freedom from two to 24 hours (OR: 2.31; 95% CI: 1.31-4.07). While ibuprofen showed the highest effect size for pain relief at 2 hours (OR: 3.21; 95% CI: 1.10-9.34), none of the studied drugs were found to significantly reduce rescue drug use.

The authors noted that high-quality studies are needed to validate findings for dihydroergotamine, as its confidence interval included null values. Clinically, ibuprofen is noted for a favorable benefit-risk profile, while sumatriptan and zolmitriptan nasal sprays may be useful for patients with nausea or vomiting. Sumatriptan/naproxen sodium may be an option for inadequate response to monotherapy.

How this fits prior evidence

This meta-analysis addresses a gap in the management of pediatric migraine by providing comparative efficacy data for multiple acute treatments. It complements existing evidence regarding the high rate of adverse events (30%) reported during pharmacological prophylaxis in pediatric patients by identifying specific options with favorable benefit-risk profiles, such as ibuprofen.

Living with a migraine as a child or teenager can be incredibly disruptive. New research looking at nearly 9,000 participants across 30 different studies helps clarify which treatments work best to stop pain quickly. The study compared several common medications against a placebo to see how well they worked for young patients.

Some options stood out for immediate relief. Ibuprofen and a combination of sumatriptan with naproxen sodium both showed strong results in providing pain freedom within two hours. While many drugs were more effective than doing nothing at all, only the sumatriptan and naproxen combination showed significantly higher odds for lasting pain freedom up to 24 hours after the initial dose.

Safety is a major factor when treating children. The study found that ibuprofen had a favorable balance of benefits and risks. Other options like nasal sprays may be helpful for kids who experience nausea or vomiting. However, some medications like zolmitriptan were linked to more side effects, while acetaminophen was very well tolerated. Because some data on certain drugs remain limited, talk to a doctor to find the best fit for your child.

What this means for you:
Ibuprofen and sumatriptan with naproxen sodium provide strong early relief for children's migraines.

Common questions

Which medicines work best for a child's migraine?

Ibuprofen and a combination of sumatriptan and naproxen sodium both showed strong results in providing pain freedom within two hours. While many drugs were more effective than a placebo, only the sumatriptan and naproxen combination was associated with significantly higher odds for lasting relief up to 24 hours.

Are there specific options for kids who feel sick to their stomach?

Yes, the study suggests that sumatriptan and zolmitriptan nasal sprays can be effective for patients who experience nausea or vomiting during a migraine. However, it is important to note that zolmitriptan was associated with a higher risk of side effects compared to other options.

Is ibuprofen safe for treating migraines in children?

The study found that ibuprofen has a favorable benefit-risk profile for treating migraines. While it showed high effectiveness for initial pain relief, some other medications like acetaminophen were also noted for having a very low risk of side effects.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BackgroundMigraine in children and adolescents not only impacts academic pursuits and family life but also have secondary psychological effects. Determining the role of acute medication for migraine treatment in this population can reduce the burden associated with migraine. This network meta-analysis aimed to identify the relative efficacy and safety of acute migraine drug in children and adolescents migraine populations.MethodsThe Cochrane Register of Controlled Trials and MEDLINE via PubMed and Embase databases were searched from inception to August 2025, only published studies in English. Double-blind randomized clinical trials evaluating the currently available acute treatments for childhood and adolescent migraines were included. The primary efficacy endpoint was pain freedom at 2 hours. Secondary efficacy endpoints included the proportion of participants with pain relief at 2 hours, pain freedom from two to 24 h, and the proportion using rescue drugs after 2 hours and up to 24 h. Adverse events (AEs) were also evaluated.ResultsThe analysis included 30 studies (involving 8,914 participants and 13 pharmacological interventions). All treatments included demonstrated higher odds ratios (ORs) compared with the placebo for pain freedom at 2 hours. Dihydroergotamine was associated with the highest ORs, but its confidence interval included null values. Sumatriptan/naproxen sodium, ibuprofen, zolmitriptan nasal spray, sumatriptan nasal spray, and rizatriptan showed statistical significance. Sumatriptan/naproxen sodium yielded the highest odds (OR: 2.91, 95% CI: 1.87–4.53), followed by ibuprofen (OR: 2.88, 95% CI: 1.47–5.64), and rizatriptan showed the lowest (OR: 1.51, 95% CI: 1.23–1.86). Only sumatriptan/naproxen sodium was associated with a significantly higher OR compared with placebo for pain freedom from two to 24 h (OR: 2.31, 95% CI: 1.31–4.07). Ibuprofen exhibited the highest effect size for pain relief at 2 hours (OR: 3.21, 95% CI: 1.10–9.34). None of the included drugs was found to reduce the use of rescue drugs from two to 24 h. Zolmitriptan was associated with the highest risk of AEs among all treatments. Acetaminophen appears to have the lowest risk of adverse events, comparable to that of a placebo.ConclusionIbuprofen can effectively relieve symptoms, characterized by a favorable benefit-risk profile. Sumatriptan and zolmitriptan nasal sprays also exhibited robust efficacy, specifically among populations with prominent nausea and vomiting. Sumatriptan/naproxen sodium merits consideration, especially in patients exhibiting an inadequate response to monotherapy. Dihydroergotamine demonstrated potential benefits in refractory and chronic migraine; however, high-quality studies are warranted to validate these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.